IELSG38A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue (MALT lymphoma)
Participants required:112 (enrolment completed)
Investigator responsible(s):A. Stathis, S. Luminari, L. Baldini, C. Thieblemont, R. Gressin, E. Zucca
Objective(s):To assess the therapeutic safety and activity of the combination of Chlorambucil and Rituximab given for 6 months, followed by 2-year maintenance treatment with subcutaneous Rituximab alone in MALT lymphomas.

Home | Go to Studies